These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 27612007)

  • 1. Effect of US Food and Drug Administration-Approved Pediatric Labeling on Dispensing of Extended-Release Oxycodone in the Outpatient Retail Setting.
    Xu J; Gill R; Cruz M; Staffa J; Lurie P
    JAMA Pediatr; 2016 Nov; 170(11):1103-1104. PubMed ID: 27612007
    [No Abstract]   [Full Text] [Related]  

  • 2. Opioid tolerance and urine drug testing among initiates of extended-release or long-acting opioids in Food and Drug Administration's Sentinel System.
    Larochelle MR; Cocoros NM; Popovic J; Dee EC; Kornegay C; Ju J; Racoosin JA
    J Opioid Manag; 2017; 13(5):315-327. PubMed ID: 29199397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rates of opioid dispensing and overdose after introduction of abuse-deterrent extended-release oxycodone and withdrawal of propoxyphene.
    Larochelle MR; Zhang F; Ross-Degnan D; Wharam JF
    JAMA Intern Med; 2015 Jun; 175(6):978-87. PubMed ID: 25895077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDA to tighten labeling on long acting opioids.
    McCarthy M
    BMJ; 2013 Sep; 347():f5581. PubMed ID: 24030791
    [No Abstract]   [Full Text] [Related]  

  • 5. The disparate treatment of medications and opiate pain medications under the law: permitting the proliferation of opiates and limiting access to treatment.
    Ferrara MM
    Seton Hall Law Rev; 2012; 42(2):741-67. PubMed ID: 22708140
    [No Abstract]   [Full Text] [Related]  

  • 6. Is pediatric labeling really necessary?
    Christensen ML; Helms RA; Chesney RW
    Pediatrics; 1999 Sep; 104(3 Pt 2):593-7. PubMed ID: 10469796
    [No Abstract]   [Full Text] [Related]  

  • 7. Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.
    Kirson NY; Shei A; White AG; Birnbaum HG; Ben-Joseph R; Rossiter LF; Michna E
    Pain Med; 2014 Sep; 15(9):1450-4. PubMed ID: 25041231
    [No Abstract]   [Full Text] [Related]  

  • 8. Off label use of antimicrobial agents in infants, children and adolescents: a time for action.
    Abramson JS; Holland ME
    Pediatr Infect Dis J; 1998 Aug; 17(8):739-44. PubMed ID: 9726350
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA approves oxycodone and acetaminophen extended-release tablets.
    J Pain Palliat Care Pharmacother; 2014 Jun; 28(2):188-9. PubMed ID: 25011144
    [No Abstract]   [Full Text] [Related]  

  • 10. New pediatric dosage rules: information and testing.
    Feeg VD
    Pediatr Nurs; 1998; 24(6):518, 613. PubMed ID: 10085992
    [No Abstract]   [Full Text] [Related]  

  • 11. The effect of abuse-deterrent extended-release oxycodone leads to inappropriate conclusions with over estimation of safety of abuse-deterrent formulations.
    Manchikanti L; Atluri S; Hirsch JA
    Pain Physician; 2015; 18(3):E445-6. PubMed ID: 26000699
    [No Abstract]   [Full Text] [Related]  

  • 12. OVERDOSED ON OPIOIDS: A deadly opioid epidemic sweeping the country has lawmakers working hard to find solutions.
    Hoback J
    State Legis; 2016 Apr; 42(4):9-13. PubMed ID: 27071212
    [No Abstract]   [Full Text] [Related]  

  • 13. Painkiller crackdown.
    Kalb C
    Newsweek; 2001 May; 137(20):38. PubMed ID: 11373803
    [No Abstract]   [Full Text] [Related]  

  • 14. Pediatric efficacy supplement for Videx EC.
    AIDS Patient Care STDS; 2008 Nov; 22(11):919. PubMed ID: 19043843
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluating potentially aberrant outpatient prescriptions for extended-release oxycodone.
    Goodman FD; Glassman P
    Am J Health Syst Pharm; 2005 Dec; 62(24):2604-8. PubMed ID: 16333058
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA set to expand pediatric information in drug product labeling.
    Am J Health Syst Pharm; 1995 Feb; 52(4):358. PubMed ID: 7757855
    [No Abstract]   [Full Text] [Related]  

  • 17. Bioequivalence of oxycodone hydrochoride extended release tablets to marketed reference products OxyContin® in Canada and US.
    Gosai P; Ducharme MP; Godfrey AR; Freeman JC; Monif T; Kumar KS; Kumar S; Mudnaik R; Katikaneni P
    Int J Clin Pharmacol Ther; 2013 Nov; 51(11):895-907. PubMed ID: 23673291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA requires boxed warning for all immediate-release opioid products.
    Thompson CA
    Am J Health Syst Pharm; 2016 May; 73(9):e114-5. PubMed ID: 27099322
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic orphans.
    Shirkey H
    Pediatrics; 1999 Sep; 104(3 Pt 2):583-4. PubMed ID: 10469793
    [No Abstract]   [Full Text] [Related]  

  • 20. A curse and a cure. Is the crackdown on an abused drug causing needless suffering?
    Kleiner C
    US News World Rep; 2001 Aug; 131(5):42-3. PubMed ID: 11499370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.